Jingfang Medicine
At a glance
- Status
- Operational
- Open positions
- None listed
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Dec 2021 | $69M | $275M | Su xin Venture Capital · CDH Investments · Qiaojing Capital · Shanjin Capital | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Jingfang Medicine in its local ecosystem
The Jingfang Medicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later13 investors entered at this stage
Huagai Capital- SCSu xin Venture Capital
CDH Investments- QCQiaojing Capital
- SCShanjin Capital
- ABABCI
- QCQingchi Capital
- PCPan Lin Capital
Baidu Ventures
- DCDeyi Capital
- XIXie Nuo Investment
- WIWenzhou Investment
HM Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jingfang Medicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jingfang Medicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







